<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01588756</url>
  </required_header>
  <id_info>
    <org_study_id>AOM08193</org_study_id>
    <nct_id>NCT01588756</nct_id>
  </id_info>
  <brief_title>Development of a New Non-radioactive Test for Measuring Glomerular Filtration Rate Using the Tetrapeptide N-acetyl-Ser-Asp-Lys-Pro-amide (AcSDKP-NH2)</brief_title>
  <acronym>AcSDKP-NH2</acronym>
  <official_title>Development of a New Non-radioactive Test for Measuring Glomerular Filtration Rate Using the Tetrapeptide N-acetyl-Ser-Asp-Lys-Pro-amide (AcSDKP-NH2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to validate a new reference marker for evaluation of renal
      function (glomerular filtration rate).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic kidney disease (CKD) is a worldwide public health problem with an increasing
      incidence and prevalence, poor outcomes (kidney failure, complications of decreased kidney
      function and cardiovascular disease), and high cost. Some of the adverse outcomes can be
      prevented or delayed by early detection and treatment. However, CKD is frequently
      underdiagnosed and undertreated. The glomerular filtration rate (GFR) is considered as the
      best index of renal function. The clinical action plan promoted by International Guidelines
      groups refers to GFR values. Despite recent improvements, prediction equations developed in
      order to estimate GFR elicit a huge lack of accuracy when considering the individual patient,
      especially in case of early CKD. Rigorous assessment of GFR requires the measurement of
      urinary or plasma clearance of an ideal exogenous filtration marker which is either
      non-radioactive (inulin, iothalamate, or iohexol) or radioactive ( 51Cr-EDTA or 99mTc DTPA.
      Measuring clearance with the use of exogenous markers is difficult to perform in clinical
      practice because it is expensive and cumbersome and needs specialised laboratories and thus,
      is underused. There is an unmet need for the development of a new non-radioactive GFR tracer
      that could combine both the analytical accuracy of radioactive tracers and the simplicity of
      its measurement. Such a tracer should improve clinical care and follow-up of patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2010</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>glomerular filtration rate</measure>
    <time_frame>between day 7 and day 21</time_frame>
    <description>NAcSDKP clearance for GFR measurement is compared to inuline and 51Cr-EDTA clearance in two phase I studies in 50 healthy subjects. GFR is first assessed at equilibrium by measuring urinary clearances of inuline and NAcSDKP continuously co-infused after a loading dose; and second by plasma clearances of 51Cr-EDTA and NAcSDKP after a single IV bolus. Optimal conditions for using NAcSDKP as a marker for GFR and the tolerability of the peptide are assessed during these studies. Then, a phase IIa study will be performed to compare the 2 methods in 45 patients with various degrees of renal failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>One month extended to 3 months safety follow up</time_frame>
    <description>all adverse events (clinical or biological adverse events)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>AcSDKP-NH2 inuline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AcSDKP-NH2 inuline, Once intravenous administration of 100 µg or less</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AcSDKP-NH2 Cr-EDTA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AcSDKP-NH2 Cr-EDTA, Once intravenous administration of 100 µg or less</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AcSDKP-NH2 inuline</intervention_name>
    <description>Once intravenous administration of 100 µg or less</description>
    <arm_group_label>AcSDKP-NH2 inuline</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AcSDKP-NH2 Cr-EDTA</intervention_name>
    <description>Once intravenous administration of 100 µg or less</description>
    <arm_group_label>AcSDKP-NH2 Cr-EDTA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Phase I: 18-35 years male

          -  Phase I: healthy volunteers

          -  Phase II: 18-80 years patients (both sex)

          -  Phase II: with Chronic Kidney Disease

        Exclusion Criteria:

          -  Phase I: Smokers

          -  Phase I: Allergic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel AZIZI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Université Paris-Descartes, Faculté de Médecine; Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Centre d'Investigations Cliniques; INSERM, CIC 9201, F-75015 Paris, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Investigation Center, European George Pompidou Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Mesmin C, Cholet S, Blanchard A, Chambon Y, Azizi M, Ezan E. Mass spectrometric quantification of AcSDKP-NH2 in human plasma and urine and comparison with an immunoassay. Rapid Commun Mass Spectrom. 2012 Jan 30;26(2):163-72. doi: 10.1002/rcm.5326.</citation>
    <PMID>22173804</PMID>
  </results_reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2012</study_first_submitted>
  <study_first_submitted_qc>April 27, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2012</study_first_posted>
  <last_update_submitted>February 27, 2017</last_update_submitted>
  <last_update_submitted_qc>February 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic kidney disease</keyword>
  <keyword>GFR</keyword>
  <keyword>Inulin</keyword>
  <keyword>51Cr-EDTA</keyword>
  <keyword>ASDKP-NH2</keyword>
  <keyword>Healthy male 18-35 yrs old, non smokers, non allergic</keyword>
  <keyword>Or Male/female 18-80 yrs old with chronic Kidney disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Goralatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

